Vertex stock faces November 30 FDA test after Q3 growth
Published on 11/09/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth broadens beyond cystic fibrosis
- Third-quarter revenue increased 12 percent as Vertex expanded contributions from newer medicines and its core cystic fibrosis portfolio.
- Management raised full-year 2026 revenue guidance and included its first full-year contribution from the Crinetics acquisition.
- The FDA has set November 30 as the target action date for povetacicept in IgA nephropathy.
Vertex Pharmaceuticals reported stronger third-quarter sales and lifted its full-year outlook on November 2, while preparing for a major regulatory decision in kidney disease. In its third-quarter release, the company said revenue for the period ended September 30 increased 12 percent year over year to 3.44 billion US dollars.
Growth came mainly from Vertex's cystic fibrosis portfolio, while newer products added to the mix. ALYFTREK generated 705.8 million US dollars in quarterly revenue, compared with 247.0 million US dollars a year earlier. CASGEVY revenue rose to 99.2 million US dollars from 16.9 million, and JOURNAVX reached 58.3 million US dollars versus 19.6 million. PALSONIFY, added through the Crinetics Pharmaceuticals acquisition, contributed 10.1 million US dollars in September.
Revenue outlook moves higher
Vertex raised its 2026 total revenue guidance to 13.15 billion to 13.25 billion US dollars, up from the previous range of 13.1 billion to 13.2 billion. The forecast includes at least 500 million US dollars of combined CASGEVY and JOURNAVX revenue and 40 million to 50 million US dollars from PALSONIFY following the September 1 closing of the Crinetics transaction.
The guidance increase came with higher spending expectations. Vertex lifted combined GAAP research and development, acquired in-process research and development, and selling, general and administrative expense guidance to 7.15 billion to 7.2 billion US dollars. Non-GAAP expense guidance rose to approximately 6.0 billion US dollars. The company attributed part of the increase to the integration of Crinetics and included approximately 500 million US dollars of compensation and transaction costs in the GAAP figures.
That cost burden was visible in the reported earnings. GAAP net income fell to 653.6 million US dollars from 1.08 billion US dollars in the year-earlier quarter, primarily because of Crinetics-related expenses. Non-GAAP net income was 1.2 billion US dollars in both periods, indicating that higher product revenue offset increased operating expenses, higher interest expense and lower interest income on the company's adjusted measure.
Kidney pipeline reaches regulatory test
The nearer-term catalyst is povetacicept, an experimental treatment for IgA nephropathy. The US Food and Drug Administration has assigned a November 30, 2026 PDUFA target action date to Vertex's application for accelerated approval. The submission is supported by interim Week 36 results from the Phase 3 RAINIER study.
Chief Executive Officer Reshma Kewalramani said a potential approval would position nephrology as Vertex's fifth commercial franchise, after cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia, acute pain, and rare endocrine diseases. The statement is forward-looking: the November 30 date is a regulatory target, not an approval.
Vertex is also advancing povetacicept in primary membranous nephropathy and generalized myasthenia gravis. The company expects to share results from its Phase 2 study in generalized myasthenia gravis in the first half of 2027. These programs could broaden the commercial opportunity, but they remain dependent on clinical and regulatory progress.
Vertex stock remains tied to catalysts
Vertex stock traded at 493.00 euros on Lang & Schwarz at 15:02 CET on Monday, November 9, 2026.
Vertex Pharmaceuticals at a glance
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Home exchange: Nasdaq
- Latest quote: 493.00 euros on Lang & Schwarz, November 9, 2026 at 15:02 CET
For investors, the earnings update combines dependable cash generation from cystic fibrosis with execution risk from a widening portfolio. The FDA decision on November 30 is the next clearly defined event, while the Crinetics integration and rising investment will shape how much of the revenue growth reaches earnings.
The broader market backdrop remains relevant for biotechnology shares through the S&P 500.
More earnings coverage and pipeline developments are available in More news and analyses on Vertex stock.
